SB-201076

• CAT Number: I036046
• CAS Number: 154566-05-9
• Molecular Formula: C18H24Cl2O6
• Molecular Weight: 407.28
• Purity: 98%
• Synonyms: SB-201076; SB 201076; SB201076
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: (2S)-2-[(2S)-8-(2,4-dichlorophenyl)-2-hydroxyoctyl]-2-hydroxybutanedioic acid
• InChI: InChI=1S/C18H24Cl2O6/c19-13-8-7-12(15(20)9-13)5-3-1-2-4-6-14(21)10-18(26,17(24)25)11-16(22)23/h7-9,14,21,26H,1-6,10-11H2,(H,22,23)(H,24,25)/t14-,18-/m0/s1
• InChIKey: NPZOIISFQXTCQN-KSSFIOAISA-N
• SMILES: C1=CC(=C(C=C1Cl)Cl)CCCCCC[C@@H](C[C@](CC(=O)O)(C(=O)O)O)O

SB-201076（Cat No.:I036046）is a small molecule compound that acts as a selective inhibitor of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). This enzyme is involved in the conversion of inactive cortisone to active cortisol in tissues like the liver and adipose tissue. By inhibiting 11β-HSD1, SB-201076 may reduce excessive cortisol production, which is linked to conditions such as obesity, type 2 diabetes, and metabolic syndrome. SB-201076 has been investigated for its potential therapeutic applications in managing diseases associated with dysregulated cortisol metabolism and metabolic disturbances.

Reference

1: Sanfilippo J, Ness M, Petscher Y, Rappaport L, Zuckerman B, Gaab N. Reintroducing Dyslexia: Early Identification and Implications for Pediatric Practice. Pediatrics. 2020 Jul;146(1):e20193046. doi: 10.1542/peds.2019-3046. Epub 2020 Jun 23. PMID: 32576595; PMCID: PMC7329249.
2: Feng X, Zhang L, Xu S, Shen AZ. ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: An updated review. Prog Lipid Res. 2020 Jan;77:101006. doi: 10.1016/j.plipres.2019.101006. Epub 2019 Sep 6. PMID: 31499095.
3: Birchenall KA, Welsh GI, López Bernal A. Metabolite Changes in Maternal and Fetal Plasma Following Spontaneous Labour at Term in Humans Using Untargeted Metabolomics Analysis: A Pilot Study. Int J Environ Res Public Health. 2019 Apr 30;16(9):1527. doi: 10.3390/ijerph16091527. PMID: 31052173; PMCID: PMC6539865.
4: Zhang C, Liu J, Huang G, Zhao Y, Yue X, Wu H, Li J, Zhu J, Shen Z, Haffty BG, Hu W, Feng Z. Cullin3-KLHL25 ubiquitin ligase targets ACLY for degradation to inhibit lipid synthesis and tumor progression. Genes Dev. 2016 Sep 1;30(17):1956-70. doi: 10.1101/gad.283283.116. PMID: 27664236; PMCID: PMC5066239.
5: Inoue N, Watanabe H, Okamura K, Kondo S, Kagami S. Are the equations for the creatinine-based estimated glomerular filtration rate applicable to the evaluation of renal function in Japanese children and adult patients receiving chemotherapy? Clin Exp Nephrol. 2015 Apr;19(2):298-308. doi: 10.1007/s10157-014-0976-z. Epub 2014 May 4. PMID: 24792810.
6: Chu KY, Lin Y, Hendel A, Kulpa JE, Brownsey RW, Johnson JD. ATP-citrate lyase reduction mediates palmitate-induced apoptosis in pancreatic beta cells. J Biol Chem. 2010 Oct 15;285(42):32606-15. doi: 10.1074/jbc.M110.157172. Epub 2010 Aug 7. PMID: 20693577; PMCID: PMC2952263.
7: Yang L, Wang DX, Zheng QY, Pan J, Huang ZT, Wang MX. Highly efficient and concise synthesis of both antipodes of SB204900, clausenamide, neoclausenamide, homoclausenamide and zeta-clausenamide. Implication of biosynthetic pathways of Clausena alkaloids. Org Biomol Chem. 2009 Jun 21;7(12):2628-34. doi: 10.1039/b901965k. Epub 2009 May 5. PMID: 19503939.
8: Yoo B. Impact of missing data on type 1 error rates in non-inferiority trials. Pharm Stat. 2010 Apr-Jun;9(2):87-99. doi: 10.1002/pst.378. PMID: 19408241.
9: Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D, Hingorani SR, Tuveson DA, Thompson CB. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell. 2005 Oct;8(4):311-21. doi: 10.1016/j.ccr.2005.09.008. PMID: 16226706.
10: Michno A, Skibowska A, Raszeja-Specht A, Cwikowska J, Szutowicz A. The role of adenosine triphosphate citrate lyase in the metabolism of acetyl coenzyme a and function of blood platelets in diabetes mellitus. Metabolism. 2004 Jan;53(1):66-72. doi: 10.1016/j.metabol.2003.07.012. PMID: 14681844.
11: Pearce NJ, Yates JW, Berkhout TA, Jackson B, Tew D, Boyd H, Camilleri P, Sweeney P, Gribble AD, Shaw A, Groot PH. The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076. Biochem J. 1998 Aug 15;334 ( Pt 1)(Pt 1):113-9. doi: 10.1042/bj3340113. PMID: 9693110; PMCID: PMC1219669.
12: van Vlijmen BJ, Pearce NJ, Bergö M, Staels B, Yates JW, Gribble AD, Bond BC, Hofker MH, Havekes LM, Groot PH. Apolipoprotein E*3-Leiden transgenic mice as a test model for hypolipidaemic drugs. Arzneimittelforschung. 1998 Apr;48(4):396-402. PMID: 9608883.